This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO) (TYCO)

This study has been completed.
Information provided by (Responsible Party):
Novartis Identifier:
First received: July 8, 2010
Last updated: March 25, 2016
Last verified: March 2016
It will be conducted as an international multicenter prospective observational cohort study in a population of ErbB2 positive metastatic breast cancer patients, whose disease has progressed after trastuzumab-containing regimen, comparing outcomes in two groups: Group 1: patients receiving Lapatinib-capecitabine immediately after 1st Trastuzumab progression (second line treatment), and Group 2: patients receiving Lapatinib-capecitabine after 2 or more lines of treatment after 1st trastuzumab progression (third line or greater).

Condition Intervention
Cancer Drug: Treatment

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Time to disease progression [ Time Frame: One year ]
    the time from the date of start of Lapatinib capecitabine treatment until date of documented disease progression by the treating physician

Secondary Outcome Measures:
  • Overall Response Rate [ Time Frame: One year ]
    the percentage of patients showing complete response (CR) and partial response (PR) to the given treatment.

  • Overall survival [ Time Frame: measured at the end of follow-up ]
    the time from the start of lapatinib capecitabine treatment until death due to any cause

Enrollment: 288
Study Start Date: February 2010
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
ErbB2+ metastatic breast cancer patients
Drug: Treatment
patients treated with Lapatinib-Capecitabine after Trastuzumab Progression

Detailed Description:
Lapatinib in combination with capecitabine is a standard of care treatment for ErbB2+ metastatic breast cancer (MBC) patients who have progressed after anthracyclines, taxanes and trastuzumab treatment. Results from the lapatinib pivotal trial showed that the addition of lapatinib to capecitabine increased median time to progression (TTP) even among heavily pre-treated patients (median of 4 prior lines of therapy). A recent ad hoc subset analysis of this trial suggested that earlier administration of lapatinib-capecitabine in MBC patients who progress after trastuzumab may produce better clinical outcomes. The TYCO study was designed to evaluate if early switch to lapatinib-capecitabine in patients with ErbB2+ MBC who have progressed on trastuzumab-containing regimen improves TTP in comparison with a later start (after several lines of therapy). Secondary objectives include Overall Response Rate (ORR), 1 year Overall Survival (OS), and description of reported serious adverse events. This is an international, multicenter, prospective, observational (non-interventional) study in 269 ErbB2+MBC patients whose disease has progressed after treatment with trastuzumab. Two cohorts will be compared; Group 1: patients receiving lapatinib-capecitabine immediately after first trastuzumab progression, and Group 2: patients receiving lapatinib-capecitabine after two or more lines of treatment after first trastuzumab progression. Eligibility criteria include females aged 18 or more with confirmed ErbB2+ MBC who have progressed after a previous trastuzumab-containing regimen, eligible to start standard therapy with lapatinib-capecitabine at approved conventional doses, as per local label approval. The study duration is of 12 months with data collection at baseline and approximately every 3 months thereafter. Patient evaluations will be conducted per standard patient care in each center and TTP will be determined by the treating physician (clinically or radiologically). Enrollment started in February 2010 and completion of accrual is estimated for December 2011.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All cases of ErbB2 positive metastatic breast cancer, receiving approved standard treatment with lapatinib-capecitabine, after trastuzumab-containing regimen progression in community setting. Patients from private and public settings.
  • Women with ErbB2+ MBC (ErbB2 expression confirmed by immunohistochemistry or FISH/CISH, either in the primary tumor or in the metastasis, according to the institution`s common practice);
  • Older than 18 years old;
  • Have received prior treatment with trastuzumab-containing regimen for ErbB2+ breast cancer;
  • Progressing after trastuzumab-containing regimen either used for the treatment of metastatic disease or progressing after adjuvant /neoadjuvant trastuzumab treatment;
  • Eligible to start standard treatment with Lapatinib-capecitabine at conventional doses, OR receiving standard treatment with
  • Lapatinib-capecitabine at conventional doses, for no longer than 10 weeks from the start of the treatment to the date of inclusion in the study;
  • Signed consent to participate and release information for this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01160094

Novartis Investigative Site
Bogota, Colombia
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Bucaramanga, Colombia
Novartis Investigative Site
Medellin, Colombia
Novartis Investigative Site
Pasto, Colombia
Novartis Investigative Site
Pereira, Colombia
Saudi Arabia
Novartis Investigative Site
Dammam, Saudi Arabia, Dammam 31444
Novartis Investigative Site
Jeddah, Saudi Arabia, 21499
Novartis Investigative Site
Jeddah, Saudi Arabia, jEDDAH 21423
Novartis Investigative Site
Jeddah, Saudi Arabia
Novartis Investigative Site
Riyadh, Saudi Arabia
Sponsors and Collaborators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Identifier: NCT01160094     History of Changes
Other Study ID Numbers: 113780
Study First Received: July 8, 2010
Last Updated: March 25, 2016

Keywords provided by Novartis:
Metastatic Breast Cancer
Breast Cancer
Observational Study

Additional relevant MeSH terms:
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors processed this record on August 23, 2017